Found 53 Enz. Inhib. hit(s) with all data for entry = 8380 TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 0.550nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 0.650nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 1.80nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 2.5nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 2.80nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 3.20nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.20nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 5.20nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 6.20nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 7.10nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 7.60nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 7.80nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 8.10nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 8.5nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 8.90nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 11nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 12nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 12nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 12nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 18nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 22nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 26nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 29nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 40nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 41nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 55nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 59nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 75nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 83nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 87nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 120nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 120nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 160nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 6.5nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 5.20nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 13nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 10nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 5.10nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 3.60nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 19nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 10nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 34nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 13nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 8.30nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 24nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 3.30nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 1.80nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Homo sapiens (Human))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataEC50: 2.80nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
